Changes of HER2 Status in Circulating Tumor Cells Compared With the Primary Tumor During Treatment for Advanced Breast Cancer

Munzone, Elisabetta; Nolè, Franco; Goldhirsch, Aron; Botteri, Edoardo; Espósito, Angela; Zorzino, Laura; Curigliano, Giuseppe; Minchella, Ida; Adamoli, Laura; Cassatella, Maria Cristina; Casadio, Chiara; Sandri, Maria Teresa

doi:10.3816/cbc.2010.n.052

Cited by 94 publications

(75 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several studies in breast cancer patients have found that HER2 expression differed between CTCs and the primary tumour. It has thus been postulated that CTCs expressing different biomarkers from the primary tumour may respond differently to treatments (13)(14)(15)(16).…”

Section: Discussionmentioning

confidence: 99%

Detection of Circulating Tumour Cells and Survival of Patients with Non-Small Cell Lung Cancer

Chudasama

Barr

Beeson

et al. 2017

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Detection of Circulating Tumour Cells and Survival of Patients with Non-Small Cell Lung Cancer

Chudasama

Barr

Beeson

et al. 2017

View full text Add to dashboard Cite

“…Changes of HER2 status in CTCs compared with the primary tumor during treatment for advanced breast cancer have also been reported (62,63 ). Detection of ERBB2 mRNA-positive CTCs after the completion of adjuvant chemotherapy may provide clinically useful information concerning the efficacy of treatment and the prognosis of patients with operable breast cancer (64 ).…”

Section: Human Epidermal Growth Factor Receptormentioning

confidence: 99%

Circulating Tumor Cells in Breast Cancer: Detection Systems, Molecular Characterization, and Future Challenges

2011

View full text Add to dashboard Cite

BACKGROUND: Circulating tumor cell (CTC) analysis is a promising new diagnostic field for estimating the risk for metastatic relapse and metastatic progression in patients with cancer.CONTENT: Different analytical systems for CTC isolation and detection have been developed as immunocytochemical and molecular assays, most including separation steps by size or biological characteristics, such as expression of epithelial-or cancer-specific markers. Recent technical advancements in CTC detection and characterization include methods based on multiplex reverse-transcription quantitative PCR and approaches based on imaging and microfilter and microchip devices. New areas of research are directed toward developing novel assays for CTC molecular characterization. QC is an important issue for CTC analysis, and standardization of micrometastatic cell detection and characterization methodologies is important for the incorporation of CTCs into prospective clinical trials to test their clinical utility. The molecular characterization of CTCs can provide important information on the molecular and biological nature of these cells, such as the status of hormone receptors and epidermal and other growth factor receptor family members, and indications of stem-cell characteristics. This information is important for the identification of therapeutic targets and resistance mechanisms in CTCs as well as for the stratification of patients and real-time monitoring of systemic therapies.

show abstract

“…Various studies have demonstrated a discrepancy between the primary tumor and the CTCs in regard to their expression of HER2 (Fehm et al 2010;Munzone et al 2010;Hayashi et al 2012), estrogen receptor alpha (Aktas et al 2011;Gradilone et al 2011b), and progesterone receptor (Aktas et al 2011). A study of patients with metastatic breast cancer, starting a new systemic therapy, demonstrated that HE2-positive CTCs, not present at baseline but at first follow-up, were associated with shorter progression-free survival (Hayashi et al 2012).…”

Section: Ctc Characterization and Monitoring Therapy Responsesmentioning

confidence: 99%

Circulating Tumor Cells as Biomarkers in Cancer

Freeman

Gray

Ziman

2014

Biomarkers in Cancer

View full text Add to dashboard Cite

show abstract

Changes of HER2 Status in Circulating Tumor Cells Compared With the Primary Tumor During Treatment for Advanced Breast Cancer

Cited by 94 publications

References 31 publications

Detection of Circulating Tumour Cells and Survival of Patients with Non-Small Cell Lung Cancer

Detection of Circulating Tumour Cells and Survival of Patients with Non-Small Cell Lung Cancer

Circulating Tumor Cells in Breast Cancer: Detection Systems, Molecular Characterization, and Future Challenges

Circulating Tumor Cells as Biomarkers in Cancer

Contact Info

Product

Resources

About